Clinical Utility of Serum Bone Turnover Markers in Postmenopausal Osteoporosis Therapy Monitoring: A Systematic Review

Seminars in Arthritis and Rheumatism

Volumn 41, Issue 2, 2011, Pages 157-169

  Funck Brentano, Thomas ^a   Biver, Emmanuel ^b   Chopin, Florence ^c   Bouvard, Beatrice ^d   Coiffier, Guillaume ^e   Souberbielle, Jean Claude ^a   Garnero, Patrick ^f   Roux, Christian ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^d ANGERS UNIVERSITY HOSPITAL   (France)

^e RENNES UNIVERSITY HOSPITAL   (France)

^f INSERM   (France)

Author keywords

Bone turnover marker; Collagen type I trimeric cross linked peptide; Drug monitoring; Medication adherence; Osteoporosis; Postmenopausal therapy

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CARBOXY TERMINAL TELOPEPTIDE; ETIDRONIC ACID; OSTEOCALCIN; PARATHYROID HORMONE DERIVATIVE; PLACEBO; PROCOLLAGEN C PROTEINASE; PROCOLLAGEN N PROTEINASE; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; TILUDRONIC ACID;

ARTICLE; BONE DENSITY; BONE TURNOVER; DRUG CHOICE; DRUG EFFICACY; DRUG REEXPOSURE; DRUG RESPONSE; FEMUR SUBTROCHANTERIC FRACTURE; FRAGILITY FRACTURE; HUMAN; JAW OSTEONECROSIS; POSTMENOPAUSE OSTEOPOROSIS; PREDICTION; PRIORITY JOURNAL; RISK REDUCTION; SYSTEMATIC REVIEW; VERTEBRA FRACTURE;

BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; FEMALE; HUMANS; OSTEOGENESIS; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 80755125271     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2011.01.005     Document Type: Article

References (84)

1. Garnero P., Sornay-Rendu E., Claustrat B., Delmas P.D. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 2000, 15(8):1526-1536.
2. Rosenquist C., Fledelius C., Christgau S., Pedersen B., Bonde M., Qvist P., et al. Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin Chem 1998, 44(11):2281-2289.
3. Garnero P., Borel O., Delmas P.D. Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clin Chem 2001, 47(4):694-702.
4. Garnero P., Hausherr E., Chapuy M.C., Marcelli C., Grandjean H., Muller C., et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 1996, 11(10):1531-1538.
5. Glover S., Gall M., Schoenborn-Kellenberger O., Wagener M., Garnero P., Boonen S., et al. Establishing a reference interval for bone turnover markers in 637 healthy, young, pre-menopausal women from UK, France, Belgium and the USA. J Bone Miner Res 2008 Jul 29.
6. Glover S., Eastell R., McCloskey E., Rogers A., Garnero P., Lowery J., et al. Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. Bone 2008, 45(6):1053-1058.
7. Garnero P., Mulleman D., Munoz F., Sornay-Rendu E., Delmas P.D. Long-term variability of markers of bone turnover in postmenopausal women and implications for their clinical use: the OFELY study. J Bone Miner Res 2003, 18(10):1789-1794.
8. Qvist P., Christgau S., Pedersen B., Schlemmer A., Christiansen C. Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone 2002, 31(1):57-61.
9. Christgau S., Bitsch-Jensen O., Hanover Bjarnason N., Gamwell Henriksen E., Qvist P., Alexandersen P., et al. Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy. Bone 2000, 26(5):505-511.
10. Garnero P., Vergnaud P., Hoyle N. Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis. Clin Chem 2008, 54(1):188-196.
11. Ueda M., Inaba M., Okuno S., Nagasue K., Kitatani K., Ishimura E., et al. Clinical usefulness of the serum N-terminal propeptide of type I collagen as a marker of bone formation in hemodialysis patients. Am J Kidney Dis 2002, 40(4):802-809.
12. Hannon R., Blumsohn A., Naylor K., Eastell R. Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J Bone Miner Res 1998, 13(7):1124-1133.
13. Eastell R., Krege J.H., Chen P., Glass E.V., Reginster J.Y. Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr Med Res Opin 2006, 22(1):61-66.
14. Lee N.K., Sowa H., Hinoi E., Ferron M., Ahn J.D., Confavreux C., et al. Endocrine regulation of energy metabolism by the skeleton. Cell 2007, 130(3):456-469.
15. Urena P., Hruby M., Ferreira A., Ang K.S., de Vernejoul M.C. Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Am Soc Nephrol 1996, 7(3):506-512.
16. Kanis J.A., Burlet N., Cooper C., Delmas P.D., Reginster J.Y., Borgstrom F., et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008, 19(4):399-428.
17. Lau E.M.C., Sambrook P., Seeman E., Leong K.H., Leung P.C., Delmas P. Guidelines for diagnosing, prevention and treatment of osteoporosis in Asia. APLAR J Rheumatol 2006, 9(1):24-36.
18. Bergmann P., Body J.J., Boonen S., Boutsen Y., Devogelaer J.P., Goemaere S., et al. Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club. Int J Clin Pract 2009, 63(1):19-26.
19. Liberati A., Altman D.G., Tetzlaff J., Mulrow C., Gotzsche P.C., Ioannidis J.P., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009, 151(4):W65-W94.
20. Bauer D.C., Black D.M., Garnero P., Hochberg M., Ott S., Orloff J., et al. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 2004, 19(8):1250-1258.
21. Bauer D.C., Garnero P., Hochberg M.C., Santora A., Delmas P., Ewing S.K., et al. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res 2006, 21(2):292-299.
22. Eastell R., Barton I., Hannon R.A., Chines A., Garnero P., Delmas P.D. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003, 18(6):1051-1056.
23. Seibel M.J., Naganathan V., Barton I., Grauer A. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate. J Bone Miner Res 2004, 19(2):323-329.
24. Delmas P.D., Licata A.A., Reginster J.Y., Crans G.G., Chen P., Misurski D.A., et al. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Bone 2006, 39(2):237-243.
25. Collette J., Bruyère O., Kaufman J., Lorenc R., Felsenberg D., Spector T., et al. Vertebral anti-fracture efficacy of strontium ranelate according to pre-treatment bone turnover. Osteoporos Int 2010, 21(2):233-241.
26. Ravn P., Clemmesen B., Christiansen C. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone 1999, 24(3):237-244.
27. Ravn P., Hosking D., Thompson D., Cizza G., Wasnich R.D., McClung M., et al. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab 1999, 84(7):2363-2368.
28. Kim S.W., Park D.J., Park K.S., Kim S.Y., Cho B.Y., Lee H.K., et al. Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis. Endocr J 2005, 52(6):667-674.
29. Nenonen A., Cheng S., Ivaska K.K., Alatalo S.L., Lehtimaki T., Schmidt-Gayk H., et al. Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. J Bone Miner Res 2005, 20(10):1804-1812.
30. Watts N.B., Jenkins D.K., Visor J.M., Casal D.C., Geusens P. Comparison of bone and total alkaline phosphatase and bone mineral density in postmenopausal osteoporotic women treated with alendronate. Osteoporos Int 2001, 12(4):279-288.
31. Kyd P.A., Vooght K.D., Kerkhoff F., Thomas E., Fairney A. Clinical usefulness of bone alkaline phosphatase in osteoporosis. Ann Clin Biochem 1998, 35(Pt 6):717-725.
32. Bauer D.C., Garnero P., Bilezikian J.P., Greenspan S.L., Ensrud K.E., Rosen C.J., et al. Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2006, 91(4):1370-1375.
33. Chen P., Satterwhite J.H., Licata A.A., Lewiecki E.M., Sipos A.A., Misurski D.M., et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 2005, 20(6):962-970.
34. Reginster J.Y., Sarkar S., Zegels B., Henrotin Y., Bruyere O., Agnusdei D., et al. Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone 2004, 34(2):344-351.
35. Bjarnason N.H., Sarkar S., Duong T., Mitlak B., Delmas P.D., Christiansen C. Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 2001, 12(11):922-930.
36. Sarkar S., Reginster J.Y., Crans G.G., Diez-Perez A., Pinette K.V., Delmas P.D. Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res 2004, 19(3):394-401.
37. Delmas P.D., Munoz F., Black D.M., Cosman F., Boonen S., Watts N.B., et al. Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis. J Bone Miner Res 2009, 24(9):1544-1551.
38. Bruyère O., Collette J., Rizzoli R., Decock C., Ortolani S., Cormier C., et al. Relationship between 3-month changes in biochemical markers of bone remodelling and changes in bone mineral density and fracture incidence in patients treated with strontium ranelate for 3 years. Osteoporos Int 2009 Oct.
39. Hochberg M.C., Greenspan S., Wasnich R.D., Miller P., Thompson D.E., Ross P.D. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002, 87(4):1586-1592.
40. Burnett-Bowie S.A., Saag K., Sebba A., de Papp A.E., Chen E., Rosenberg E., et al. Prediction of changes in bone mineral density in postmenopausal women treated with once-weekly bisphosphonates. J Clin Endocrinol Metab 2009 Jan 13.
41. Hochberg M.C., Silverman S.L., Barr C.E., Miller P.D. The utility of changes in serum levels of C-terminal telopeptide of type I collagen in predicting patient response to oral monthly ibandronate therapy. J Clin Densitom 2010, 13(2):181-189.
42. Kumm J., Ivaska K.K., Rohtla K., Vaananen K., Tamm A. Urinary osteocalcin and other markers of bone metabolism: the effect of risedronate therapy. Scand J Clin Lab Invest 2008, 68(6):459-463.
43. Tahtela R., Seppanen J., Laitinen K., Katajamaki A., Risteli J., Valimaki M.J. Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide. Osteoporos Int 2005, 16(9):1109-1116.
44. Clowes J.A., Peel N.F., Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 2004, 9(3):1117-1123.
45. Delmas P.D., Vrijens B., Eastell R., Roux C., Pols H.A., Ringe J.D., et al. Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 2007, 92(4):1296-1304.
46. Kung A.W.C., Rachman I.A., Adam J.M.F., Roeshadi D., Torralba T., Navarra S., et al. Impact of bone marker feedback on adherence to once monthly ibandronate for osteoporosis among Asian postmenopausal women. Int J Rheum Dis 2009, 12(3):216-224.
47. Black D.M., Schwartz A.V., Ensrud K.E., Cauley J.A., Levis S., Quandt S.A., et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006, 296(24):2927-2938.
48. Watts N.B., Chines A., Olszynski W.P., McKeever C.D., McClung M.R., Zhou X., et al. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 2008, 19(3):365-372.
49. Greenspan S.L., Emkey R.D., Bone H.G., Weiss S.R., Bell N.H., Downs R.W., et al. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002, 137(11):875-883.
50. Marx R.E., Cillo J.E., Ulloa J.J. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007, 65(12):2397-2410.
51. Kunchur R., Need A., Hughes T., Goss A. Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws. J Oral Maxillofac Surg 2009, 67(6):1167-1173.
52. Lazarovici T.S., Mesilaty-Gross S., Vered I., Pariente C., Kanety H., Givol N., et al. Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates. J Oral Maxillofac Surg 2010, 68(9):2241-2247.
53. Kwon Y.D., Kim D.Y., Ohe J.Y., Yoo J.Y., Walter C. Correlation between serum C-terminal cross-linking telopeptide of type I collagen and staging of oral bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2009, 67(12):2644-2648.
54. Bagan J.V., Jimenez Y., Gomez D., Sirera R., Poveda R., Scully C. Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates. Oral Oncol 2008, 44(11):1088-1089.
55. Baim S., Miller P.D. Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. J Bone Miner Res 2009, 24(4):561-574.
56. Khosla S., Burr D., Cauley J., Dempster D.W., Ebeling P.R., Felsenberg D., et al. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2008, 66(6):1320-1321. author reply 1321-2.
57. Khosla S., Burr D., Cauley J., Dempster D.W., Ebeling P.R., Felsenberg D., et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007, 22(10):1479-1491.
58. Sayed-Noor A.S., Sjoden G.O. Subtrochanteric displaced insufficiency fracture after long-term alendronate therapy-a case report. Acta Orthop 2008, 79(4):565-567.
59. Kwek E.B., Goh S.K., Koh J.S., Png M.A., Howe T.S. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?. Injury 2008, 39(2):224-231.
60. Kwek E.B., Koh J.S., Howe T.S. More on atypical fractures of the femoral diaphysis. N Engl J Med 2008, 359(3):316-317. author reply 317-8.
61. Visekruna M., Wilson D., McKiernan F.E. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 2008, 93(8):2948-2952.
62. Neviaser A.S., Lane J.M., Lenart B.A., Edobor-Osula F., Lorich D.G. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 2008, 22(5):346-350.
63. Lenart B.A., Lorich D.G., Lane J.M. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 2008, 358(12):1304-1306.
64. Lenart B.A., Neviaser A.S., Lyman S., Chang C.C., Edobor-Osula F., Steele B., et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 2009, 20(8):1353-1362.
65. Odvina C.V., Zerwekh J.E., Rao D.S., Maalouf N., Gottschalk F.A., Pak C.Y. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005, 90(3):1294-1301.
66. Armamento-Villareal R., Napoli N., Panwar V., Novack D. Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. N Engl J Med 2006, 355(19):2048-2050.
67. Giusti A., Hamdy N.A., Papapoulos S.E. Atypical fractures of the femur and bisphosphonate therapy: A systematic review of case/case series studies. Bone 2010, 47(2):169-180.
68. Souberbielle J.C., Carlier M.C., Bianchi F., Genty V., Jacob N., Kamel S., et al. [Prescription of bone remodeling markers in hospitals]. Ann Biol Clin (Paris) 2002, 60(5):571-579.
69. Cummings S., San Martin J., McClung M., Siris E., Eastell R., Reid I., et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009, 361(8):756-765.
70. Grados F., Brazier M., Kamel S., Duver S., Heurtebize N., Maamer M., et al. Effects on bone mineral density of calcium and vitamin D supplementation in elderly women with vitamin D deficiency. Joint Bone Spine 2003, 70(3):203-208.
71. Grados F., Brazier M., Kamel S., Mathieu M., Hurtebize N., Maamer M., et al. Prediction of bone mass density variation by bone remodeling markers in postmenopausal women with vitamin D insufficiency treated with calcium and vitamin D supplementation. J Clin Endocrinol Metab 2003, 88(11):5175-5179.
72. Rabenda V., Hiligsmann M., Reginster J. Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence. Exp Opin Pharmacother 2009, 10(14):2303-2315.
73. Briot K., Ravaud P., Dargent-Molina P., Zylberman M., Liu-Leage S., Roux C. Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience. Osteoporos Int 2009, 20(4):625-630.
74. Briot K., Tremollieres F., Thomas T., Roux C. How long should patients take medications for postmenopausal osteoporosis?. Joint Bone Spine 2007, 74(1):24-31.
75. Dowd R., Recker R., Heaney R. Study subjects and ordinary patients. Osteoporos Int 2000, 11(6):533-536.
76. Dormuth C., Patrick A., Shrank W., Wright J., Glynn R., Sutherland J., et al. Statin adherence and risk of accidents: a cautionary tale. Circulation 2009, 119(15):2051-2057.
77. Majima T., Shimatsu A., Satoh N., Komatsu Y., Fukao A., Ninomiya K., et al. Three-month changes in bone turnover markers and bone mineral density response to raloxifene in Japanese postmenopausal women with osteoporosis. J Bone Miner Metab 2008, 26(2):178-184.
78. Garnero P., Darte C., Delmas P.D. A model to monitor the efficacy of alendronate treatment in women with osteoporosis using a biochemical marker of bone turnover. Bone 1999, 24(6):603-609.
79. Braga de Castro Machado A., Hannon R., Eastell R. Monitoring alendronate therapy for osteoporosis. J Bone Miner Res 1999, 14(4):602-608.
80. Greenspan S.L., Parker R.A., Ferguson L., Rosen H.N., Maitland-Ramsey L., Karpf D.B. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res 1998, 13(9):1431-1438.
81. Greenspan S.L., Resnick N.M., Parker R.A. Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab 2005, 90(5):2762-2767.
82. Ivaska K.K., Pettersson K., Nenonen A., Uusi-Rasi K., Heinonen A., Kannus P., et al. Urinary osteocalcin is a useful marker for monitoring the effect of alendronate therapy. Clin Chem 2005, 51(12):2362-2365.
83. Ravn P., Thompson D.E., Ross P.D., Christiansen C. Biochemical markers for prediction of 4-year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis. Bone 2003, 33(1):150-158.
84. Atmaca A., Gedik O. Effects of alendronate and risedronate on bone mineral density and bone turnover markers in late postmenopausal women with osteoporosis. Adv Ther 2006, 23(6):842-853.